Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action

A. K. M. Azad; Shadma Fatima; Alexander Capraro; Shafagh A. Walters; Fatemeh Vafaee

doi:10.1016/j.patter.2021.100325

Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action

A. K. M. Azad, Shadma Fatima, Alexander Capraro, Shafagh A. Walters, Fatemeh Vafaee

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical in silico investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.

Original language	English
Article number	100325
Number of pages	10
Journal	Patterns
Volume	2
Issue number	9
DOIs	https://doi.org/10.1016/j.patter.2021.100325
Publication status	Published - 2021

Open Access - Access Right Statement

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.patter.2021.100325

Cite this

@article{68f1d8b36cdf4f25990712741b8f01f2,

title = "Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action",

abstract = "An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical in silico investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.",

author = "Azad, {A. K. M.} and Shadma Fatima and Alexander Capraro and Walters, {Shafagh A.} and Fatemeh Vafaee",

year = "2021",

doi = "10.1016/j.patter.2021.100325",

language = "English",

volume = "2",

journal = "Patterns",

issn = "2666-3899",

publisher = "Cell Press",

number = "9",

}

TY - JOUR

T1 - Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action

AU - Azad, A. K. M.

AU - Fatima, Shadma

AU - Capraro, Alexander

AU - Walters, Shafagh A.

AU - Vafaee, Fatemeh

PY - 2021

Y1 - 2021

N2 - An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical in silico investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.

AB - An effective monotherapy to target the complex and multifactorial pathology of SARS-CoV-2 infection poses a challenge to drug repositioning, which can be improved by combination therapy. We developed an online network pharmacology-based drug repositioning platform, COVID-CDR (http://vafaeelab.com/COVID19repositioning.html), that enables a visual and quantitative investigation of the interplay between the primary drug targets and the SARS-CoV-2-host interactome in the human protein-protein interaction network. COVID-CDR prioritizes drug combinations with potential to act synergistically through different, yet potentially complementary, pathways. It provides the options for understanding multi-evidence drug-pair similarity scores along with several other relevant information on individual drugs or drug pairs. Overall, COVID-CDR is a first-of-its-kind online platform that provides a systematic approach for pre-clinical in silico investigation of combination therapies for treating COVID-19 at the fingertips of the clinicians and researchers.

UR - https://hdl.handle.net/1959.7/uws:63423

U2 - 10.1016/j.patter.2021.100325

DO - 10.1016/j.patter.2021.100325

M3 - Article

SN - 2666-3899

VL - 2

JO - Patterns

JF - Patterns

IS - 9

M1 - 100325

ER -

Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action

Abstract

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this